Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311342 | 0.87 | SRR (0.48) | ITGB1ITGA4 | |
| SCHEMBL6487486 | 0.87 | SRR (0.48) | ITGB1ITGA4 | |
| SCHEMBL13311344 | 0.83 | CYP1A2 (0.42) | SLC6A3ITGB1ITGA4 | |
| Cyclohexylamine SCHEMBL8637515 | 0.81 | SRR (0.45) | ITGB1ITGA4 | |
| SCHEMBL7050550 | 0.79 | SIGMAR1 (0.39) | SLC6A3ITGB1ITGA4 | |
| SCHEMBL14330746 | 0.79 | SLC6A3 (0.43) | SLC6A3ITGB1ITGA4 | |
| SCHEMBL1743566 | 0.79 | SLC6A3 (0.61) | SLC6A3GAA | |
| SCHEMBL14233517 | 0.79 | SLC6A3 (0.61) | SLC6A3GAA | |
| SCHEMBL14211627 | 0.79 | SLC6A3 (0.61) | SLC6A3GAA | |
| SCHEMBL9394999 | 0.78 | ACE (0.49) | SLC6A3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-6974869-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050261311-A1 | Piperizinones as modulators of chemokine receptor activity | DELUCCA GEORGE V | 2005-11-24 | — | — | US | disclosed |
| US-20030144277-A1 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-31 | — | — | US | disclosed |
| WO-2003024401-A2 | PIPERIZINONES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144277-A1 | Piperizinones as modulators of chemokine receptor activity | CCR3, CCR1, CCR5 | SLC6A3 2805/4885ITGB1 1614/4885ITGA4 1403/4885 |
| US-20050261311-A1 | Piperizinones as modulators of chemokine receptor activity | CCR3, CCR1, CCR5 | SLC6A3 2548/4885ITGB1 1922/4885ITGA4 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.